Back to today’s briefing

Story perspectives

Tune Therapeutics Secures $175M for Hepatitis B Breakthrough

1/13/2025

29 4

Summary

Story summary

Tune Therapeutics, with roots in Seattle and Durham, has raised an impressive $175 million in Series B funding to propel its groundbreaking epigenome editing platform. This investment will fuel clinical trials for Tune-401, a promising treatment for chronic Hepatitis B, impacting over 250 million lives worldwide. The company is poised to broaden its pipeline and innovate further therapies.

1 of 1

Story summary

Tune Therapeutics, with roots in Seattle and Durham, has raised an impressive $175 million in Series B funding to propel its groundbreaking epigenome editing platform. This investment will fuel clinical trials for Tune-401, a promising treatment for chronic Hepatitis B, impacting over 250 million lives worldwide. The company is poised to broaden its pipeline and innovate further therapies.